http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-103773889-B
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_217f2be73fd6be0be36dd55803d3bec5 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-686 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 |
| filingDate | 2014-02-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2015-07-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cb370d4a8241d3478e2f6bb308f6d832 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6634e5ff139640f71a66170cf2436335 |
| publicationDate | 2015-07-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-103773889-B |
| titleOfInvention | HRM (high resolution melting) method and kit for clinically detecting EGFR (epidermal growth factor receptor) gene mutation |
| abstract | The invention discloses an HRM (high resolution melting) method and kit for clinically detecting EGFR (epidermal growth factor receptor) gene mutation. The DNA (deoxyribonucleic acid) of a sample to be detected is extracted, and PCR (polymerase chain reaction) amplification and HRM scanning analysis are performed by use of primers shown by SEQ ID No.1-30; the type of the EGFR gene mutation is judged according to the scanning analysis result; if the HRM scanning no-parting sample is negative, the HRM scanning parting sample is positive. The kit disclosed by the invention comprises the primers, a negative control, a positive control, a PCR reagent, LCGREEN and the like. All primers of the kit can perform PCR reaction at the same temperature, the detection sensitivity is high, the specificity is strong, the reaction system is small, the detection sample is widely available, the reaction is simple and quick, the reagent is cheap, and the flux is high. By adopting the method and kit disclosed by the invention, the whole detection process is simple to operate, time-saving, low in cost, suitable for quickly detecting the EGFR gene mutation of clinical tumor patients, and good for guiding the clinical individualized medication. |
| priorityDate | 2014-02-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 60.